

## ASX RELEASE

### Volpara receives regulatory clearance in Taiwan

Wellington, NZ, 23 October 2017: [Volpara Health Technologies](#) (“Volpara”; ASX: VHT), a digital health company focused on the early detection of breast cancer by improving quality of screening, is pleased to announce that VolparaDensity™ and VolparaDose™ have received regulatory clearance as a Class II medical device from the Taiwan Food and Drug Administration (TFDA).

VolparaEnterprise™ is not classified as a medical device in Taiwan, and does not require regulatory approval.

Taiwan, which has a target population for screening of over 670,000 women, is a potential major market for Volpara. It is estimated that Taiwan has around 300 digital mammography machines, and it is one of world’s largest users of computer-aided detection in mammography outside of the US, in line with its status as a leading adopter of computer technology.

The incidence of breast cancer is also rapidly increasing in Taiwan, with the number of cases almost doubling in the last 20 years and forecast to approach Western levels over the next 15 years. For this reason, breast cancer screening and increasing the compliance surrounding screening is an area of focus for the government. Women aged 45-69 are encouraged to undergo a breast screen every two years.

Volpara will launch the products in Taiwan via its Taiwanese Distributor (sales and installation), supported by the Volpara APAC sales team. The company already has two research sites in place - Changhua Christian Hospital in Changhua City which has commenced an evaluation of VolparaEnterprise Analytics, and set to be the first VolparaEnterprise customer in Asia. Whilst, the Tri-Service General Hospital in Taipei, has been using VolparaDensity in clinical research since 2014.

“We regard Taiwan as a very important market – both for its track record as being early adopters of new technologies and the increased focus on improvement of breast screening, in light of the growing rate of breast cancer,” said Dr Ralph Highnam, Chief Executive of Volpara.

“We also know it has a higher population of women with dense breasts compared to the West. A study conducted at the Changhua Christian Hospital on nearly 100,000 women with VolparaDensity, showed 82.1 % of their population had dense breasts, compared to a more typical 40-50% in the West. This is potentially a strong driver for uptake in Taiwan of both VolparaDensity for clinical applications and VolparaEnterprise for breast clinic management, as both offerings are machine and language agnostic.”

ENDS.

## **About Volpara Health Technologies Limited (ASX: VHT)**

Founded in 2009 from research originally conducted at Oxford University, VHT is based in Wellington, New Zealand and facilitates the early detection of breast cancer through its digital health solutions to enable personalised, high-quality breast cancer screening based on objective measurements of breast density.

VHT has a number of patents and trademarks and regulatory clearances, including FDA and CE, supporting its technology and services. An ASX-listed company that raised A\$20M through an IPO and subsequent share placement and rights issue in 2016, VHT has customers and/or research projects in 36 countries.

[www.volparasolutions.com](http://www.volparasolutions.com)

### **For further information, please contact:**

Ralph Highnam, CEO  
Volpara Health Technologies  
ralph.highnam@volparasolutions.com  
t: +64 21 149 0541

Kyahn Williamson  
WE Buchan  
kwilliamson@buchanwe.com.au  
t: +61 3 9866 4722